Core Viewpoint - Immuron Limited, an Australian biopharmaceutical company, is set to present at the Emerging Growth Conference on June 13, 2024, highlighting its innovative products and growth potential [1][4]. Company Overview - Immuron Limited (ASX: IMC; NASDAQ: IMRN) focuses on developing and commercializing orally delivered targeted polyclonal antibodies for treating infectious diseases [7]. - The company’s flagship product, Travelan®, is an orally administered passive immunotherapy that reduces the likelihood of travelers' diarrhea caused by pathogenic bacteria [8][9]. Conference Details - CEO Steven Lydeamore will present for 12 minutes at 2:00 PM US Eastern Standard Time and will address questions from attendees [2]. - The conference aims to connect public companies with individual and institutional investors, showcasing new products and major announcements [4][5]. Product Information - Travelan® is a highly purified tabletized preparation of hyperimmune bovine antibodies that binds to diarrhea-causing bacteria, preventing colonization [8]. - The product is registered in Australia and licensed in Canada, and it is sold as a dietary supplement in the U.S. for digestive tract protection [9]. Technology Platform - Immuron's proprietary technology utilizes polyclonal immunoglobulins derived from engineered hyper-immune bovine colostrum, allowing for the development of medicines targeting various infectious diseases [11]. - The platform can produce specific immunoglobulins that remain active in the gastrointestinal tract, effectively neutralizing pathogens [11].

Company Overview - Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases [2][3] - The company is listed on both the Australian Securities Exchange (ASX: IMC) and NASDAQ (NASDAQ: IMRN) [2] Product Information - Travelan® is an orally administered passive immunotherapy designed to reduce the likelihood of contracting travelers' diarrhea, which is caused by pathogenic bacteria [3] - Travelan® is a highly purified tabletized preparation of hyper immune bovine antibodies that bind to diarrhea-causing bacteria, preventing colonization [3][8] - In Australia, Travelan® is registered as a medicine, while in Canada it is a licensed natural health product, and in the U.S., it is sold as a dietary supplement [3] Technology Platform - Immuron's proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum, allowing for the production of highly specific immunoglobulins to any enteric pathogen [5] - The platform technology enables the development of medicines across a wide range of infectious diseases by blocking viruses or bacteria at mucosal surfaces [5] Research and Development - IMM-124E, developed using Immuron's platform technology, is produced from the colostrum of immunized cattle and contains significant levels of polyclonal antibodies specific for enterotoxigenic E. coli (ETEC) [6][7] - The antibodies in IMM-124E exhibit stronger binding and neutralizing activity against various LPS antigens compared to those from unvaccinated cattle [8]

MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Dr Roger Aston has resigned from his position as Non-Executive Director effective today. Roger was appointed as a Director in 2012 and served as Non-Executive Chairman from 2012 to 2023. Immuron over the past few years has been ongoing with significant positive change. We have accelerated our commercial activities through higher ...

Core Viewpoint - Immuron Limited announces the resignation of Dr. Roger Aston as Non-Executive Director and the appointment of Dr. Jeannie Joughin, highlighting ongoing positive changes and strategic advancements within the company [1][4][5]. Company Developments - Immuron has experienced significant positive changes, accelerating commercial activities through enhanced marketing and strategic intent [2]. - The company is focusing on long-term improvements in manufacturing and supply chain to meet anticipated demand over the next decade [3]. - Immuron's partnership with the US Military is yielding strong evidence for preventative strategies against infectious diseases [3]. Leadership Changes - Dr. Roger Aston has resigned due to family commitments in the UK after 12 years of service, contributing significantly to the company's direction and capital raising during challenging periods [4]. - Dr. Jeannie Joughin has been appointed as a Non-Executive Director, bringing extensive experience from her roles in major pharmaceutical companies, which will support Immuron's clinical and commercial programs [5]. Product Focus - Immuron's proprietary technology involves developing orally delivered targeted polyclonal antibodies for treating infectious diseases, particularly through its product Travelan®, which helps prevent traveler's diarrhea [6][7][10]. - The company is advancing its research on Clostridium difficile preventive and curative products, showing great potential for future development [3].

MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to advise our Chief Executive Officer Steven Lydeamore will be presenting at Peak Asset Management's Peak Sky High luncheon in Melbourne on June 1, 2024. A copy of the presentation slide deck is available on the Company's website. https://www.immuron.com.au/corporate-presentations/ This release has been authorised by the directors ...

MELBOURNE, Australia, May 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference, on Wednesday 8th May. The next Emerging Growth Conference will be presented on Wednesday, 8 May, 2024. This live, interactive online event will give existing sharehol ...

MELBOURNE, Australia, May 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference, on Wednesday 8th May. The next Emerging Growth Conference will be presented on Wednesday, 8 May, 2024. This live, interactive online event will give existing sharehol ...

MELBOURNE, Australia, May 03, 2024 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Stephen Anastasiou has resigned from his position as Non-Executive Director effective today to focus on his other business interests. Stephen has served as a Director since 2013 and has provided valued contributions and experienced counsel to the Company. During Stephen's tenure, Immuron launched Travelan® into the USA and Canadi ...

Sales Highlights: Global FYTD Mar 2024 AUD$3.6 million up 154% on (prior comparative period) pcpMar 2024 Quarter AUD$1.3 million up 51% on pcp and 75% on last quarter   Australia FYTD Mar 2024 AUD$2.8 million up 234% on pcpMar 2024 Quarter AUD$0.9 million up 66% on pcp and 99% on last quarter   USA FYTD Mar 2024 AUD$0.8 million up 35% on pcpMar 2024 Quarter AUD$0.3 million up 7% on pcp and 18% on last quarterSales commenced on Walmart.com MELBOURNE, Australia, April 10, 2024 (GLOBE NEWSWIRE) -- Immuron Lim ...

Exhibit 99.1 Immuron 31 DECEMBER 2023 HALF YEAR REPORT Immuron Limited Appendix 4D Half-year 31 December 2023 | Name of entity: | Immuron Limited | | --- | --- | | ABN: | 80 063 114 045 | | Half-year ended: | 31 December 2023 | | Previous period: | 31 December 2022 | Results for announcement to the market | | | | $ | | --- | --- | --- | --- | | Revenue from ordinary activities | Up | 303.6% to | 2,355,580 | | Net loss after tax (from ordinary activities) for the period attributable to members | Up | (4.8)% ...